Reinfection With SARS-CoV-2: Implications for Vaccines

被引:78
|
作者
Cohen, Jeffrey, I [1 ]
Burbelo, Peter D. [2 ]
机构
[1] NIH, Lab Infect Dis, Bldg 50,Room 6134,50 South Dr,MSC8007, Bethesda, MD 20892 USA
[2] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA
基金
美国国家卫生研究院;
关键词
SARS-CoV-2; COVID-19; reinfection; coronavirus; SARS; HUMORAL IMMUNITY; CORONAVIRUS; INFECTIONS; ANTIBODIES; VIRUS;
D O I
10.1093/cid/ciaa1866
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become pandemic and the duration of protective immunity to the virus is unknown. Cases of persons reinfected with the virus are being reported with increasing frequency. At present it is unclear how common reinfection with SARS-CoV-2 is and how long serum antibodies and virus-specific T cells persist after infection. For many other respiratory virus infections, including influenza and the seasonal coronaviruses that cause colds, serum antibodies persist for only months to a few years and reinfections are very common. Here we review what is known about the duration of immunity and reinfection with coronaviruses, including SARS-CoV-2, as well as the duration of immunity to other viruses and virus vaccines. These findings have implications for the need of continued protective measures and for vaccines for persons previously infected with SARS-CoV-2.
引用
收藏
页码:E4223 / E4228
页数:6
相关论文
共 50 条
  • [31] The Current Update of Vaccines for SARS-CoV-2
    Hoang Duc Ha
    Nguyen Minh Duc
    Pham Minh Thong
    ELECTRONIC JOURNAL OF GENERAL MEDICINE, 2020, 17 (05):
  • [32] Re: SARS-CoV-2 Vaccines in Development
    Clemens, J. Quentin
    JOURNAL OF UROLOGY, 2021, 206 (01): : 139 - 139
  • [33] Development of vaccines against SARS-CoV-2
    Leon-Lara, Ximena
    Otero-Mendoza, Francisco
    ACTA PEDIATRICA DE MEXICO, 2020, 41 (04): : S23 - S26
  • [34] Immunology of SARS-CoV-2 infections and vaccines
    Schenten, Dominik
    Bhattacharya, Deepta
    ADVANCES IN IMMUNOLOGY, VOL 151, 2021, 151 : 49 - 97
  • [35] Immunogenicity of SARS-CoV-2 vaccines in with cancer
    Kakkassery, Helen
    Carpenter, Esme
    Patten, Piers E. M.
    Irshad, Sheeba
    TRENDS IN MOLECULAR MEDICINE, 2022, 28 (12) : 1082 - 1099
  • [36] Maintaining Safety with SARS-CoV-2 Vaccines
    Rolla, Giovanni
    Brussino, Luisa
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (10):
  • [37] SARS-CoV-2 virus: Vaccines in development
    Huang, Qingrui
    Yan, Jinghua
    FUNDAMENTAL RESEARCH, 2021, 1 (02): : 131 - 138
  • [38] Influenza Virus and SARS-CoV-2 Vaccines
    Sandor, Adam M.
    Sturdivant, Michael S.
    Ting, Jenny P. Y.
    JOURNAL OF IMMUNOLOGY, 2021, 206 (11): : 2509 - 2520
  • [39] The variants of SARS-CoV-2 and the challenges of vaccines
    Han, Xiucui
    Ye, Qing
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (04) : 1366 - 1372
  • [40] Maintaining Safety with SARS-CoV-2 Vaccines
    Castells, Mariana C.
    Phillips, Elizabeth J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 643 - 649